A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs ACH 4471 (Primary) ; Eculizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 26 Mar 2018 Planned initiation date changed from 31 Mar 2018 to 15 Apr 2018.
- 15 Mar 2018 Status changed from planning to not yet recruiting.
- 12 Feb 2018 According to an Achillion media release, interim data from this study is expected in fourth quarter 2018.